Skip to main content

ULTRA-DD

Innovative Medicines Initiative LogoEfpia logoEuropean Commission Research and Innovation logo

Search

  • Overview
    • Objectives and disease focus
    • Deliverables
      • Executive Summary 2020 Report
      • Executive Summary 2019 Report
      • Executive Summary 2018 Report
    • Organisation
      • Scientific Committee
      • Leadership
    • Participants
    • News
    • Contact
  • Tissue Platforms
    • Diseases
    • Cell Assay Datasets
  • Probes
    • Chemical Probes
    • Biological probes
  • Antibodies
  • Structures
  • ChromoHub
  • Publications

Development of Pyridine-based Inhibitors for the Human Vaccinia-related Kinases 1 and 2.

  • Read more about Development of Pyridine-based Inhibitors for the Human Vaccinia-related Kinases 1 and 2.

Serafim, R., de Souza Gama, F. H., Dutra, L. A., Dos Reis, C. V., Vasconcelos, S., da Silva Santiago, A., … Couñago, R. M. (2019). Development of Pyridine-based Inhibitors for the Human Vaccinia-related Kinases 1 and 2. ACS medicinal chemistry letters, 10(9), 1266–1271.

Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target.

  • Read more about Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target.

Alam, M., Sanchez-Azqueta, A., Janha, O., Flannery, E., Mahindra, A., Mapesa, K., ... Tobin A. (2019). Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science, 365(6456), eaau1682.

Open laboratory notebooks: good for science, good for society, good for scientists.

  • Read more about Open laboratory notebooks: good for science, good for society, good for scientists.

Schapira, M., Open Lab Notebook Consortium, & Harding, R. J. (2019). Open laboratory notebooks: good for science, good for society, good for scientists. F1000Research, 8, 87.

Target highlights in CASP13: experimental target structures through the eyes of their authors.

  • Read more about Target highlights in CASP13: experimental target structures through the eyes of their authors.

Lepore, R., Kryshtafovych, A., Alahuhta, M., Veraszto, H. A., Bomble, Y. J., Bufton, J. C., … Schwede, T. (2019). Target highlights in CASP13: Experimental target structures through the eyes of their authors. Proteins, 87(12), 1037–1057.

Discovery of first in vivo active inhibitors of soluble epoxide hydrolase (sEH) phosphatase domain.

  • Read more about Discovery of first in vivo active inhibitors of soluble epoxide hydrolase (sEH) phosphatase domain.

Kramer, J., Woltersdorf, S., Duflot, T., Hiesinger, K., Lillich, F., Knöll, F., ... Proschak, E. (2019). Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain. Journal Of Medicinal Chemistry, 62(18), 8443-8460.

Targeting an EGFR water network using novel 4-anilinoquin(az)olines inhibitors for chordoma.

  • Read more about Targeting an EGFR water network using novel 4-anilinoquin(az)olines inhibitors for chordoma.

Asquith, C., Maffuid, K., Laitinen, T., Torrice, C., Tizzard, G., Crona, D., & Zuercher, W. (2019). Targeting an EGFR Water Network with 4‐Anilinoquin(az)oline Inhibitors for Chordoma. Chemmedchem, 14(19), 1693-1700.

Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.

  • Read more about Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.

Taylor, A., Swewczyk, M., Kennedy, S., Trush, V., Wu, H., Zeng, H., ... Owen, D. (2019). Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3–9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase. Journal Of Medicinal Chemistry, 62(17), 7669-7683.

Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

  • Read more about Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Fong, J., Pignata, L., Goy, P., Kawabata, K., Lee, S., Koh, C., ... Guccione, E. (2019). Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell, 36(2), 194-209.e9.

The MLL1 trimeric catalytic complex is a dynamic conformational ensemble stabilized by multiple weak interactions.

  • Read more about The MLL1 trimeric catalytic complex is a dynamic conformational ensemble stabilized by multiple weak interactions.

Kaustov, L., Lemak, A., Wu, H., Faini, M., Fan, L., Fang, X., … Arrowsmith, C. H. (2019). The MLL1 trimeric catalytic complex is a dynamic conformational ensemble stabilized by multiple weak interactions. Nucleic acids research, 47(17), 9433–9447.

Plasticity at the DNA recognition site of the MeCP2 mCG-binding domain.

  • Read more about Plasticity at the DNA recognition site of the MeCP2 mCG-binding domain.

Lei, M., Tempel, W., Chen, S., Liu, K., & Min, J. (2019). Plasticity at the DNA recognition site of the MeCP2 mCG-binding domain. Biochimica Et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1862(9), 194409.

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to 2019
The ULTRA-DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115766], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author’s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
This website is licensed under a CC-BY licence | Accessibility